台灣肝臟研究學會(TASL) | 財團法人台灣肝臟研究暨教育基金會(TASLF)

The 2st TASL-AASLD Joint Symposium

Trends of HCV-HCC risk after DAAs treatment in Taiwan
影片長度：
Chen-Hua Liu
The 2st TASL-AASLD Joint Symposium

Trends of HBV-HCC risk after NUCs treatment in Taiwan
影片長度：
Tsung-Hui Hu
The 2st TASL-AASLD Joint Symposium

Trends of HCV-HCC risk after DAAs treatment in the U. S.
影片長度：
Amit Singal
The 2st TASL-AASLD Joint Symposium

Trends of HBV-HCC risk after NUC treatment in the U.S.
影片長度：
Anna Suk-Fong Lok
The 2st TASL-AASLD Joint Symposium

Hepatocellular carcinoma in NAFLD/NASH
影片長度：
Hashem El-Serag
The 1st TASL-AASLD Joint Symposium: HBV Eliminatio

New biomarkers for HBV management
影片長度：
Dr. Tai-Chung Tseng
The 1st TASL-AASLD Joint Symposium: HBV Eliminatio

How to achieve WHO goal to eliminate HBV in 2030: Efforts from Taiwan
影片長度：
Prof. Ding-Shinn Chen
The 1st TASL-AASLD Joint Symposium: HBV Eliminatio

WHO efforts towards elimination of HBV in the rest of the World
影片長度：
Prof. K. Rajender Reddy
The 1st TASL-AASLD Joint Symposium: HBV Eliminatio

Definition of HBV cure and strategies to achieve HBV cure: Updates from 2019 EASL-AASLD HBV treatmen
影片長度：
Prof. Anna Suk-Fong Lok
The 1st TASL-AASLD Joint Symposium: HBV Eliminatio

Finite nucleos(t)ide analogue therapy in HBeAg-negative chronic hepatitis B: an emerging paradigm sh
影片長度：
Prof. Yun-Fan Liaw
The 1st TASL-AASLD Joint Symposium: HBV Eliminatio

Indications for hepatitis B treatment – are current guidelines too strict?
影片長度：
Prof. Anna Suk-Fong Lok
第一頁 < 1 2 > 到最後 ，前往第 頁